Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response
Executive Summary
Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006